239 related articles for article (PubMed ID: 32152715)
1. Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs.
Kaye PM; Cruz I; Picado A; Van Bocxlaer K; Croft SL
Semin Immunopathol; 2020 Jun; 42(3):247-264. PubMed ID: 32152715
[TBL] [Abstract][Full Text] [Related]
2. Comparative proteomic analysis of
Dinç M; Yalçın T; Çavuş İ; Özbilgin A
Parasitology; 2022 Mar; 149(3):298-305. PubMed ID: 34758895
[TBL] [Abstract][Full Text] [Related]
3. Immunoregulation in human American leishmaniasis: balancing pathology and protection.
Gollob KJ; Viana AG; Dutra WO
Parasite Immunol; 2014 Aug; 36(8):367-76. PubMed ID: 24471648
[TBL] [Abstract][Full Text] [Related]
4. Imaging host-Leishmania interactions: significance in visceral leishmaniasis.
Forestier CL
Parasite Immunol; 2013; 35(9-10):256-66. PubMed ID: 23772814
[TBL] [Abstract][Full Text] [Related]
5. In vivo imaging of transgenic Leishmania parasites in a live host.
Thalhofer CJ; Graff JW; Love-Homan L; Hickerson SM; Craft N; Beverley SM; Wilson ME
J Vis Exp; 2010 Jul; (41):. PubMed ID: 20689512
[TBL] [Abstract][Full Text] [Related]
6. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.
Zijlstra EE
PLoS Negl Trop Dis; 2014; 8(11):e3258. PubMed ID: 25412435
[TBL] [Abstract][Full Text] [Related]
7. Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.
Coutinho De Oliveira B; Duthie MS; Alves Pereira VR
Hum Vaccin Immunother; 2020 Apr; 16(4):919-930. PubMed ID: 31634036
[TBL] [Abstract][Full Text] [Related]
8. Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis.
Verma S; Kumar R; Katara GK; Singh LC; Negi NS; Ramesh V; Salotra P
PLoS One; 2010 Apr; 5(4):e10107. PubMed ID: 20404924
[TBL] [Abstract][Full Text] [Related]
9. Immunodetection and molecular determination of visceral and cutaneous Leishmania infection using patients' urine.
Mirzaei A; Ahmadipour F; Cannet A; Marty P; Delaunay P; Perrin P; Dorkeld F; Sereno D; Akhoundi M
Infect Genet Evol; 2018 Sep; 63():257-268. PubMed ID: 29847780
[TBL] [Abstract][Full Text] [Related]
10. Immunoproteomics and phage display in the context of leishmaniasis complexity.
Ludolf F; Ramos FF; Coelho EAF
Front Immunol; 2023; 14():1112894. PubMed ID: 36845148
[TBL] [Abstract][Full Text] [Related]
11. Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review.
Kelleci K; Allahverdiyev A; Bağirova M; Ihlamur M; Abamor EŞ
J Vector Borne Dis; 2023; 60(2):125-141. PubMed ID: 37417162
[TBL] [Abstract][Full Text] [Related]
12. Leishmaniasis in Turkey: Visceral and cutaneous leishmaniasis caused by Leishmania donovani in Turkey.
Özbilgin A; Harman M; Karakuş M; Bart A; Töz S; Kurt Ö; Çavuş İ; Polat E; Gündüz C; Van Gool T; Özbel Y
Acta Trop; 2017 Sep; 173():90-96. PubMed ID: 28587839
[TBL] [Abstract][Full Text] [Related]
13. Leishmaniasis: recognition and management with a focus on the immunocompromised patient.
Choi CM; Lerner EA
Am J Clin Dermatol; 2002; 3(2):91-105. PubMed ID: 11893221
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Vaccines Against Leishmania Based on Patent Applications.
Thomaz-Soccol V; Ferreira da Costa ES; Karp SG; Junior Letti LA; Soccol FT; Soccol CR
Recent Pat Biotechnol; 2018; 12(1):21-32. PubMed ID: 28494723
[TBL] [Abstract][Full Text] [Related]
15. Adaptation of Leishmania donovani to cutaneous and visceral environments: in vivo selection and proteomic analysis.
McCall LI; Zhang WW; Dejgaard K; Atayde VD; Mazur A; Ranasinghe S; Liu J; Olivier M; Nilsson T; Matlashewski G
J Proteome Res; 2015 Feb; 14(2):1033-59. PubMed ID: 25536015
[TBL] [Abstract][Full Text] [Related]
16. Place of Serology in the Diagnosis of Zoonotic Leishmaniases With a Focus on Visceral Leishmaniasis Due to
Lévêque MF; Lachaud L; Simon L; Battery E; Marty P; Pomares C
Front Cell Infect Microbiol; 2020; 10():67. PubMed ID: 32158704
[TBL] [Abstract][Full Text] [Related]
17. Dendritic Cells and Leishmania Infection: Adding Layers of Complexity to a Complex Disease.
Feijó D; Tibúrcio R; Ampuero M; Brodskyn C; Tavares N
J Immunol Res; 2016; 2016():3967436. PubMed ID: 26904694
[TBL] [Abstract][Full Text] [Related]
18. Vaccine candidates for leishmaniasis: a review.
Nagill R; Kaur S
Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
[TBL] [Abstract][Full Text] [Related]
19. Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.
Dayakar A; Chandrasekaran S; Kuchipudi SV; Kalangi SK
Front Immunol; 2019; 10():670. PubMed ID: 31024534
[TBL] [Abstract][Full Text] [Related]
20. The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis.
Gürbüz Çolak N; Çetin Uyanikgil EÖ; Özbel Y; Töz S
Acta Parasitol; 2022 Sep; 67(3):1354-1363. PubMed ID: 35857275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
